1177 — Sino Biopharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapNeutral

Annual income statement for Sino Biopharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	24,234	23,647	26,861	28,780	26,199
Cost of Revenue
Gross Profit	19,308	18,465	21,529	22,985	21,210
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	18,425	18,308	21,611	22,410	19,769
Operating Profit	5,809	5,340	5,251	6,371	6,431
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	5,691	5,013	18,573	5,779	5,410
Provision for Income Taxes
Net Income After Taxes	4,788	4,341	16,615	5,003	4,613
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	2,762	2,771	14,608	2,544	2,332
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	2,762	2,771	14,126	2,311	2,543
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.147	0.147	0.762	0.123	0.113
Dividends per Share